Tyrosine kinase inhibitors (TKIs) such as pazopanib (GlaxoSmithKline, London, UK) and sunitinib (Pfizer) are approved cancer therapies and target receptors from multiple growth factor families, including receptors for FGF, PDGF and VEGF [138,139]. The gene discussed is VEGFA; the disease is cancer.